Daiichi Sankyo has discovered novel ENHERTU®, designed to address the treatment needs of adult patients facing unresectable or metastatic HER2 positive solid tumours that have progressed despite previous treatment and who have exhausted other viable treatment options.
ENHERTU has proven effective in the treatment of patients with HER2 positive metastatic colourectal cancer who have undergone two or more prior treatment regimens. ENHERTU is composed of a HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload, an exatecan derivative, through a stable tetrapeptide-based cleavable linker.
ENHERTU represents a significant advancement in the field of cancer therapy, as it is a specifically engineered HER2 directed antibody drug conjugate (ADC) that is jointly developed and commercialised by Daiichi Sankyo and AstraZeneca.
It is the first therapy of its kind to exhibit potential benefits across a range of challenging-to-treat cancer types. This achievement holds great promise for patients with various HER2 expressing solid tumours who currently face a bleak prognosis.
ENHERTU, at a dosage of 5.4 mg/kg, has received approval in over 50 countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. This approval is extended to individuals who have previously undergone one or more anti-HER2-based regimens, whether in the metastatic, neoadjuvant, or adjuvant treatment settings, and have experienced disease recurrence during or within six months of completing their therapy.
ENHERTU is a new therapeutic approach offering hope to patients with a range of HER2 expressing solid tumours. Its innovative design and successful clinical trials represent a significant step forward in the battle against these challenging cancers.
